Chemi-Verse™ CLK2 Kinase Assay Kit
The Chemi-Verse™ CLK2 Kinase Assay Kit is designed to measure CLK2 (CDC like kinase 2) kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified recombinant CLK2 kinase (amino acids 137-end), kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.
- ADP-Glo™ Kinase Assay (Promega #V6930)
- DTT (Dithiothreitol), 1M, optional
- Microplate reader capable of reading luminescence
- Adjustable micropipettor and sterile tips
- 30°C incubator
| Catalog # | Name | Amount | Storage |
| 40197 | CLK2, GST-Tag* | 2.5 µg | -80°C |
| 79334 | 5x Kinase Buffer 1 | 1.5 ml | -20°C |
| 79686 | 500 µM ATP | 50 µl | -20°C |
| 78514 | Myelin Basic Protein (MBP), 5 mg/ml | 50 µl | -20°C |
| 79696 | White 96-well plate | 1 | Room Temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
CDC-like kinase 2 (CLK2) is part of the dual-specificity protein kinase (DSK) family that phosphorylate serine/arginine rich (SR) proteins that are part of the spliceosomal complex and also regulate non-splicing proteins. It is involved in cell cycle progression, apoptosis, the DNA replication checkpoint, and regulation of telomere length. Dysfunction in pathways regulated by CLK2 can result in inflammatory and neurodegenerative diseases such as Alzheimer’s disease, in hyperglycemia, and in cancer. CLK2 is upregulated in breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and GSC (glioma stem-like cell). CLK2 also contributes to fatty acid oxidation and ketogenesis and is involved in fatty liver disease. Recent findings demonstrated that CLK kinases activate PTP-1B (protein-tyrosine phosphatase) family members, and this phosphatase may be an important cellular target of CLK. The use of Lorecivivint, a CLK2 inhibitor, in a clinical trial for osteoarthritis was found to be effective and safe. The development of CLK2 inhibitors and a deeper understanding of its role in the multiple pathways where it is involved will prove crucial for the treatment of CLK2-linked diseases.
Song M., et al., 2023 Signal Transduction and Targeted Therapy 8: 148.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.